射血分数保留心衰死亡与致残预后模型
本研究利用DELIVER试验的6263例HFpEF患者数据开发预后模型,并在PARAGON-HF(4796例)和I-PRESERVE(4128例)中验证。复合终点模型含11个常规变量,1年C统计量0.73(95%CI 0.71-0.75),验证队列分别为0.71和0.75,区分度优于MAGGIC评分和NT-proBNP。
要点
- 11变量模型可预测HFpEF患者1年和2年心衰住院或心血管死亡风险。
- 模型区分度优于MAGGIC评分和NT-proBNP,与生物标志物模型相似。
- 已开发在线计算器,便于临床进行个体化风险评估。
核心结论
- 基于常规变量的HFpEF预后模型在大型试验中开发并验证,区分度良好且优于NT-proBNP和MAGGIC评分,有助于高危患者识别和治疗决策。
研究设计与样本
- 利用DELIVER试验6263例患者数据开发模型,在PARAGON-HF(4796例)和I-PRESERVE(4128例)中验证。
- 采用多因素分析从30个基线候选变量中逐步筛选变量,分析时间为2023年1月至6月。
主要发现
- 复合终点模型含11个变量:NT-proBNP、6个月内HFH、肌酐、糖尿病、地理区域、HF病程、SGLT2i治疗、COPD、TIA/卒中、既往HFH、心率。
- 模型1年C统计量0.73(95%CI 0.71-0.75),PARAGON-HF为0.71(95%CI 0.69-0.74),I-PRESERVE为0.75(95%CI 0.73-0.78)。
- 模型优于MAGGIC评分(1年C统计量0.60,95%CI 0.58-0.63;delta C统计量0.13,95%CI 0.10-0.15;P<.001)。
- 模型优于NT-proBNP单独(1年C统计量0.66,95%CI 0.64-0.68;delta C统计量0.07,95%CI 0.05-0.08;P<.001)。
- 全因和心血管死亡模型也表现良好。
临床怎么用
- 可使用在线计算器基于11个常规变量计算HFpEF患者1年和2年心血管死亡或心衰住院风险。
- 模型有助于识别高危患者,辅助临床治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions. OBJECTIVE: To develop and validate a novel prediction model for clinical outcomes in patients with HFpEF using routinely collected variables and to compare it with a biomarker-driven approach. DESIGN, SETTING, AND PARTICIPANTS: Data were used from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial to derive the prediction model, and data from the Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction (PARAGON-HF) and the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trials were used to validate it. The outcomes were the composite of HF hospitalization (HFH) or cardiovascular death, cardiovascular death, and all-cause death. A total of 30 baseline candidate variables were selected in a stepwise fashion using multivariable analyses to create the models. Data were analyzed from January 2023 to June 2023. EXPOSURES: Models to estimate the 1-year and 2-year risk of cardiovascular death or hospitalization for heart failure, cardiovascular death, and all-cause death. RESULTS: Data from 6263 individuals in the DELIVER trial were used to derive the prediction model and data from 4796 individuals in the PARAGON-HF trial and 4128 individuals in the I-PRESERVE trial were used to validate it. The final prediction model for the composite outcome included 11 variables: N-terminal pro-brain natriuretic peptide (NT-proBNP) level, HFH within the past 6 months, creatinine level, diabetes, geographic region, HF duration, treatment with a sodium-glucose cotransporter 2 inhibitor, chronic obstructive pulmonary disease, transient ischemic attack/stroke, any previous HFH, and heart rate. This model showed good discrimination (C statistic at 1 year, 0.73; 95% CI, 0.71-0.75) in both validation cohorts (C statistic at 1 year, 0.71; 95% CI, 0.69-0.74 in PARAGON-HF and 0.75; 95% CI, 0.73-0.78 in I-PRESERVE) and calibration. The model showed similar discrimination to a biomarker-driven model including high-sensitivity cardiac troponin T and significantly better discrimination than the Meta-Analysis Global Group in Chronic (MAGGIC) risk score (C statistic at 1 year, 0.60; 95% CI, 0.58-0.63; delta C statistic, 0.13; 95% CI, 0.10-0.15; P < .001) and NT-proBNP level alone (C statistic at 1 year, 0.66; 95% CI, 0.64-0.68; delta C statistic, 0.07; 95% CI, 0.05-0.08; P < .001). Models derived for the prediction of all-cause and cardiovascular death also performed well. An online calculator was created to allow calculation of an individual's risk. CONCLUSIONS AND RELEVANCE: In this prognostic study, a robust prediction model for clinical outcomes in HFpEF was developed and validated using routinely collected variables. The model performed better than NT-proBNP level alone. The model may help clinicians to identify high-risk patients and guide treatment decisions in HFpEF.
引用
- McDowell, Kondo, Talebi, et al. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2024. PMID: 38536153. doi:10.1001/jamacardio.2024.0284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。